M&A Deal Summary

Appili Therapeutics Acquires FUJIFILM Toyama Chemical s Clinical Stage Antifungal Program

On November 21, 2019, Appili Therapeutics acquired life science company FUJIFILM Toyama Chemical s Clinical Stage Antifungal Program from FUJIFILM Toyama Chemical

Acquisition Highlights
  • This is Appili Therapeutics’ 1st transaction in the Life Science sector.
  • This is Appili Therapeutics’ 1st transaction in Japan.

M&A Deal Summary

Date 2019-11-21
Target FUJIFILM Toyama Chemical s Clinical Stage Antifungal Program
Sector Life Science
Buyer(s) Appili Therapeutics
Sellers(s) FUJIFILM Toyama Chemical
Deal Type Divestiture

Target

FUJIFILM Toyama Chemical s Clinical Stage Antifungal Program

Tokyo, Japan
FUJIFILM Toyama Chemical Co., Ltd.'s Clinical Stage Antifungal Program (T-2307) is a developer of novel antifungal drugs.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Appili Therapeutics

Halifax, Nova Scotia, Canada

Category Company
Founded 2015
Sector Life Science
DESCRIPTION

Appili Therapeutics is a biopharmaceutical company focused on anti-infective drug development. Appili provides drug development programs for unmet patient needs across a broad spectrum of infectious diseases. Appili Therapeutics was founded in 2015 and is based in Halifax, Canada.


DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
Country (Japan) 1 of 1
Year (2019) 1 of 1

Seller(S) 1

SELLER

FUJIFILM Toyama Chemical

Tokyo, Japan

Category Company
Founded 1968
Sector Life Science
DESCRIPTION

FUJIFILM Toyama Chemical Co., Ltd. is a provider of research, development, manufacture, and sales of small molecule pharmaceutical products. FUJIFILM Toyama Chemical Co., Ltd. was founded in 1968 and is based in Tokyo, Japan.


DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
Country (Japan) 1 of 1
Year (2019) 1 of 1